NLRP3 and neoplasm: This is supported by preclinical studies showing that NLRP3 activation contributes to the recruitment of granulocytic myeloid-derived suppressor cells into tumor tissues, thereby dampening the resulting antitumor immune response, and the pharmacologic inhibition of NLRP3 blocked the immune suppressive effects of granulocytic myeloid-derived suppressor cells and significantly augmented the efficacy of anti–PD-1 antibody immunotherapy [60].